SIGA Technologies, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 7, 2024. SIGA is a commercial-stage pharmaceutical company whose principal product is TPOXX, sold to U.S. and international government customers.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Total revenue | $25.4 million | $8.3 million |
| Operating income (loss) | $11.3 million | ($2.1 million) |
| Net income (loss) | $10.3 million | ($0.9 million) |
| Diluted EPS | $0.14 | ($0.01) |
| Operating cash flow | ($6.1 million) | $24.4 million |
Product sales and supportive-service revenue was $23.9 million, up from $5.7 million; R&D revenue was $1.6 million, down from $2.6 million. U.S. revenue was $17.5 million and international revenue was $8.0 million, compared with no international revenue in Q1 2023. Operating margin was approximately 44% versus approximately negative 25% a year earlier.
Cash and cash equivalents were $143.9 million at quarter-end, down from $150.1 million at December 31, 2023. Current assets were $227.9 million and current liabilities $74.8 million. The balance sheet presents no borrowings line item; total liabilities were $78.2 million. Inventory was $63.7 million. Operating cash outflow primarily reflected a $21.8 million income-tax payment, partly offset by customer receipts. The company reported $1.9 million of other income, mainly interest income.
Material changes and notable items
- Revenue growth chiefly reflected approximately $14.7 million of oral TPOXX deliveries under the BARDA contract and international sales; Q1 2023 had no product-delivery revenue under that BARDA contract or international-contract revenue.
- SG&A increased to $7.9 million from $4.2 million, primarily due to international promotion fees, higher executive compensation, and professional fees. R&D expense fell to $3.1 million from $5.0 million, mainly as PEP-program activity declined.
- Operating cash flow shifted to an outflow from an inflow in the prior-year quarter. The company used $0.2 million in financing activities, versus $7.6 million for share repurchases in Q1 2023.
- The board declared a $0.60-per-share special dividend, totaling approximately $42.7 million. It was payable at March 31 and paid April 11, 2024; the payment reduced cash after quarter-end.
- Effective June 1, 2024, SIGA assumes primary responsibility for international promotion and sales of oral TPOXX. Meridian retains limited, non-exclusive rights in specified markets and receives a reduced, high-single-digit promotion fee there. The amended agreement expires May 31, 2026.
Outlook, risks, and contingencies
- Management says liquidity is sufficient for anticipated needs for at least the next 12 months. No numeric full-year revenue or earnings guidance is provided.
- The BARDA contract contemplates up to $602.5 million in total payments: $407.1 million related to exercised options and up to $143.7 million of unexercised options. BARDA decides whether to exercise those remaining options. SIGA estimates the remaining oral and IV product options would need to be exercised in 2024 to approximately maintain historical stockpile levels of unexpired product; this is not a committed order.
- Current performance obligations total $68.7 million. Product-delivery obligations are expected to be recognized within 24 months; R&D obligations within four years. The filing notes government contracts may be modified or terminated and options may not be exercised.
- SIGA is targeting a supplemental NDA for a smallpox post-exposure prophylaxis indication within the next 12 months. An mpox indication submission could occur as early as 2025, subject to trial results, enrollment, and outbreak conditions. Three randomized, placebo-controlled mpox trials were active at quarter-end.
- Risks include government procurement decisions and contract changes, regulatory and clinical uncertainty, supply-chain or manufacturing delays, and uncertainty in the developing international biodefense market. Management reported no material changes to the risk factors in its 2023 Form 10-K. Pending claims are not expected by management to have a material adverse effect; purchase commitments for manufacturing were approximately $13.6 million.
Important facts for investors to verify
- Whether BARDA exercises the remaining oral and IV options, and the timing and economics of any resulting deliveries.
- Whether the PEP filing target is met and whether mpox trials produce data supporting a potential label expansion.
- How international sales and costs evolve under SIGA’s expanded sales responsibility and amended Meridian arrangement.
- Cash and working-capital levels after the special-dividend payment, including collections of unbilled receivables and future tax payments.
- Delivery schedules, product shelf life, manufacturing capacity, and the use or recoverability of the $63.7 million inventory balance.